Position in SYRE
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$4,293,503
+$1,575,865 QoQ
Shares Held
85,121
+2.6% QoQ
Ownership
0.098%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 19%
Shared 0%
None 81%
Common Shares in SYRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026RHUMBLINE ADVISERS holds $1,238,289,073 across 287 Biotechnology names. SYRE ranks #51 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
423,140 | $188,948,935 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
157,781 | $121,907,911 | |
| 3 | INCY |
Incyte Corp
|
693,665 | $65,287,749 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
195,277 | $64,611,300 | |
| 5 | INSM |
INSMED Inc
|
272,615 | $44,578,004 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
164,542 | $31,106,665 | |
| 7 | EXEL |
Exelixis, Inc.
|
723,931 | $31,049,400 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
1,113,266 | $30,837,468 |
All Filings in SYRE
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,293,503 | 85,121 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $2,717,638 | 82,956 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $1,188,518 | 70,914 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $1,095,324 | 73,168 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $903,931 | 56,023 | Shares | Sole | 2025-05-29 | |
| 2024-12-31 | $1,342,254 | 57,657 | Shares | Sole | 2025-05-29 | |
| 2024-09-30 | $1,586,228 | 53,935 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $1,220,074 | 51,896 | Shares | Sole | 2024-08-01 | |
| No filing history on record for this holder in this stock. | ||||||